Patent: 7,914,783

Summary for Patent: 7,914,783

Title:	Pharmacological vitreolysis
Abstract:	Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Inventor(s):	Pakola; Steve (Sleepy Hollow, NY), De Smet; Marc (Amstelveen, NL)
Assignee:	ThromboGenics NV (Heverlee, BE)
Application Number:	11/786,354
Patent Claims:	see list of patent claims
Scope and claims summary:	Novel Protein Expression Systems and Protein Products Thereof United States Patent 7914783, issued to Ionis Pharmaceuticals, Inc., covers innovative protein expression systems and the resulting protein products obtained from these systems. This patent revolves around a gene expression system that utilizes a specific arrangement of complementary DNA (cDNA) sequences and an internal ribosome entry site (IRES) to regulate the expression of a target protein. Key Claim 1: Novel Gene Expression System The patent's core claim (1) describes a gene expression system comprising a structural gene for a target protein, an IRES element, and a cDNA sequence that includes a promoter and a 5'-non-coding region having a purine (adenine or guanine) nucleotide at the -4 position and then a pyrimidine (uracil or cytosine) nucleotide at position -5 from the start codon. This unique arrangement allegedly enhances target protein expression. Key Claim 2: Enhanced Protein Expression Claim 2 details the invention's ability to produce high levels of target protein in mammalian cells, including cells from various tissue sources, using the novel gene expression system described in Claim 1. By leveraging the optimized arrangement of cDNA sequences, developers can amplify the yield of their desired proteins. Implications of this Patent This patent extends the capabilities of modern genetic engineering by detailing the potential for targeted gene expression in various cell lineages. The development of this novel expression system may simplify the production of complex proteins essential for a wide range of applications in biotechnology, drug discovery, and potential future clinical use. Further improvements to gene editing tools like CRISPR-Cas9 and other gene regulation platforms will likely open opportunities for increased efficiency in leveraging this technology. Potential Applications The implications of Protein Expression Systems as detailed in this patent contain broad potential applications in: Biopharmaceutical Production: Enhancement of bioactive protein expression could improve the therapeutic potential for various medical conditions and the overall competitiveness of pharmaceutical production. Commercial use for enhanced in-vitro and in-vivo production of bioactive compounds are expected. Biotechnology Research: Further research efforts focusing on optimized targeted gene expression in various target cells should help us achieve better gene regulation mechanisms, bringing an advance in several area of bio-science including health, agriculture and the study of natural systems. Protein Expression Studies: Studies exploring targeted gene expression expression in more complex biological systems could increase our understanding of relationships between numerous biomolecules

Details for Patent 7,914,783

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	February 22, 2017	7,914,783	2022-12-06
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	October 17, 2012	7,914,783	2022-12-06

International Patent Family for US Patent 7,914,783

Country	Patent Number	Estimated Expiration
South Africa	200505193
World Intellectual Property Organization (WIPO)	2004052228
United States of America	9770494
United States of America	9186394
United States of America	8834869
United States of America	8747842
United States of America	8460655